ArticleCancer2025
Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04229537 (To Evaluate Safety and Efficacy of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma and Colorectal Cancer), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Evaluate Safety and Efficacy of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma and Colorectal Cancer: a Phase Ⅰb, Open-label, Multicenter Study
Who cites it
2 citing papers in PubMed.
- Subgroup-specific predictive biomarkers in peripheral blood lymphocyte subsets for immune checkpoint inhibitor response in advanced esophageal squamous cell carcinoma: a prospective study.Journal of thoracic disease · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis trial evaluated the efficacy and safety of anti-programmed cell death 1 antibody (SCT-I10A) and anti-epidermal growth factor receptor (EGFR) antibody (SCT200) in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC) (trial registration number: NCT04229537).
methodsThis multicenter, open-label, phase 1b clinical trial enrolled patients with advanced ESCC refractory or intolerant to standard chemotherapy. Patients who had not received prior treatment with programmed death-(ligand)1 (PD-(L)1) immune checkpoint inhibitors (ICIs) or anti-EGFR antibodies comprised cohort 1A, and those who had previously failed treatment with PD-(L)1 ICIs or anti-EGFR antibodies comprised cohort 1B. Eligible patients were treated with SCT200 and SCT-I10A.
resultsSeventy patients were enrolled. The objective response rate was 25.7%, with a median overall survival and progression-free survival of 6.90 months and 3.98 months, respectively. Twenty-nine patients previously underwent ICI treatment with an objective response rate of 17.24%, median overall survival of 6.08 months, and median progression-free survival of 3.98 months. Grade 3 or higher adverse events were observed in 43.3% and 52.5% of patients in cohort 1A and 1B, respectively.
conclusionsSCT-I10A plus SCT200 demonstrated durable antitumor activity with a manageable safety profile in previously treated patients with advanced ESCC, even in patients who had previously failed anti-PD-(L)1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.